Evidence for a role of endogenous cannabinoids in the modulation of acute and tonic pain sensitivity.
The competitive CB1 receptor antagonist SR141716A was used to test the hypothesis that endogenous cannabinoids modulate tonic pain sensitivity. Pretreatment with the antagonist significantly enhanced the response to a chemical nociceptive stimulus in the formalin test. Postreatment with the antagonist 5 min following the induction of tonic pain produced hyperalgesia during the tonic phase only. These findings suggest that endogenous cannabinoids serve naturally to modulate the maintenance of pain following repeated noxious stimulation.
Strangman
N M
NM
Schrier Research Laboratory, Department of Psychology, Brown University, P.O. Box 1853, 89 Waterman Street, Providence, RI 02912, USA.
Patrick
S L
SL
Hohmann
A G
AG
Tsou
K
K
Walker
J M
JM
D000208:Acute Disease; D000700:Analgesics / Q000494:pharmacology; D000818:Animals; D048588:Benzoxazines; D002186:Cannabinoids / Q000037:antagonists & inhibitors / Q000378:metabolism*; D004202:Disinfectants; D005557:Formaldehyde; D006930:Hyperalgesia / Q000503:physiopathology*; D009025:Morpholines / Q000494:pharmacology; D009281:Naphthalenes / Q000494:pharmacology; D017288:Pain Threshold / Q000187:drug effects / Q000502:physiology*; D010880:Piperidines / Q000494:pharmacology; D011720:Pyrazoles / Q000494:pharmacology; D051381:Rats; D017207:Rats, Sprague-Dawley; D000077285:Rimonabant
D000700:Analgesics; D048588:Benzoxazines; D002186:Cannabinoids; D004202:Disinfectants; D009025:Morpholines; D009281:Naphthalenes; D010880:Piperidines; D011720:Pyrazoles; D005557:Formaldehyde; C070417:(3R)-((2,3-dihydro-5-methyl-3-((4-morpholinyl)methyl)pyrrolo-(1,2,3-de)-1,4-benzoxazin-6-yl)(1-naphthalenyl))methanone; D000077285:Rimonabant